S von Mackensen1, W Kalnins2, J Krucker3, J Weiss4, W Miesbach5, M Albisetti6,7, I Pabinger8, J Oldenburg9. 1. Institute of Medical Psychology, University Medical Centre, Hamburg, Germany. 2. German Haemophilia Society (DHG), Hamburg, Germany. 3. Swiss Haemophilia Society (SHG), Altstätten, Switzerland. 4. Austrian Haemophilia Society (ÖHG), Vienna, Austria. 5. Haemophilia Centre, Medical Clinic II, Institute of Transfusion Medicine, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. 6. University Children's Hospital Zürich, Zürich, Switzerland. 7. Swiss Hemophilia Network, Altstà Tten, Switzerland. 8. Haemophilia Treatment Centre, Medical University of Vienna, Vienna, Austria. 9. Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn AöR, Bonn, Germany.
Abstract
INTRODUCTION: National Member Organisations (NMO) of persons with haemophilia (PWH) from the DACH Region (D = Germany, A = Austria, CH = Switzerland) were interested to better understand PWH's expectations and concerns of extended half-life (EHL) factor concentrates (FC) before availability in these countries. METHODS: Based on an expert meeting and focus groups conducted across Germany a survey for haemophilia patients and their parents was developed and was sent out to 2,644 PWH. RESULTS: One thousand and seven questionnaires were sent back (38.1%); 743 adults and 262 parents. Most patients had haemophilia A (84.5%), were severely affected (73.7%), received prophylaxis (57%) and used recombinant FC (60.2%). One-quarter did not know the correct half-life of their FC [HA/FVIII: 26%, HB/FIX: 31.1%]. Four percent were unsatisfied with their current FC, mainly with short half-life of FC and difficult manageability. They expected from new EHL products less frequent injections (55.2%), better efficacy (32.1%) and safety/no side effects (15.7%); 59.5% would be willing to switch to new products if they have a prolonged half-life and the same safety of the current FC. They wish more information about half-life (84.4%), possible side-effects (81.3%) and efficacy (77%) and wanted to receive information about new products from their haemophilia treater (76.3%) and the newsletter of their NMO (74.3%). Significant differences across countries were found. CONCLUSIONS: The representative survey could show that although PWH were generally satisfied with their current FC, the majority would be willing to switch to EHL products assuming half-life is prolonged and has the same safety of the current FC.
INTRODUCTION: National Member Organisations (NMO) of persons with haemophilia (PWH) from the DACH Region (D = Germany, A = Austria, CH = Switzerland) were interested to better understand PWH's expectations and concerns of extended half-life (EHL) factor concentrates (FC) before availability in these countries. METHODS: Based on an expert meeting and focus groups conducted across Germany a survey for haemophiliapatients and their parents was developed and was sent out to 2,644 PWH. RESULTS: One thousand and seven questionnaires were sent back (38.1%); 743 adults and 262 parents. Most patients had haemophilia A (84.5%), were severely affected (73.7%), received prophylaxis (57%) and used recombinant FC (60.2%). One-quarter did not know the correct half-life of their FC [HA/FVIII: 26%, HB/FIX: 31.1%]. Four percent were unsatisfied with their current FC, mainly with short half-life of FC and difficult manageability. They expected from new EHL products less frequent injections (55.2%), better efficacy (32.1%) and safety/no side effects (15.7%); 59.5% would be willing to switch to new products if they have a prolonged half-life and the same safety of the current FC. They wish more information about half-life (84.4%), possible side-effects (81.3%) and efficacy (77%) and wanted to receive information about new products from their haemophilia treater (76.3%) and the newsletter of their NMO (74.3%). Significant differences across countries were found. CONCLUSIONS: The representative survey could show that although PWH were generally satisfied with their current FC, the majority would be willing to switch to EHL products assuming half-life is prolonged and has the same safety of the current FC.
Authors: Amit Chhabra; Dean Spurden; Patrick F Fogarty; Bartholomew J Tortella; Emily Rubinstein; Simon Harris; Andreas M Pleil; Jennifer Mellor; Jonathan de Courcy; José Alvir Journal: Blood Coagul Fibrinolysis Date: 2020-04 Impact factor: 1.061
Authors: Erna C van Balen; Marjolein L Wesselo; Bridget L Baker; Marjan J Westerman; Michiel Coppens; Cees Smit; Mariëtte H E Driessens; Frank W G Leebeek; Johanna G van der Bom; Samantha C Gouw Journal: Patient Date: 2020-04 Impact factor: 3.883
Authors: Cihan Ay; Clemens Feistritzer; Joachim Rettl; Gerhard Schuster; Anna Vavrovsky; Leonard Perschy; Ingrid Pabinger Journal: Sci Rep Date: 2021-06-21 Impact factor: 4.379